Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Olusola Abiola LADOKUN

Olusola Abiola LADOKUN

Lead City University, Ibadan, Nigeria

Title: GC-MS and molecular docking studies of Hunteria umbellata methanolic extract as a potent anti-diabetic

Biography

Biography: Olusola Abiola LADOKUN

Abstract

The purpose of this study was to investigate the diabetic effect of phytocompounds synthesized from Hunteria umbellata using GC-MS analysis and molecular docking studies. Peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists are beneficial in the treatment of diabetes by stimulating insulin sensitivity and antagonizing hepatic gluconeogenesis. The aim of the present study was to investigate PPAR-γ agonist property of phytocompounds from Hunteria umbellata using in-silico approach.  Molecular docking of Hunteria umbellata on human PPAR-γ protein was determined by Auto/Vina in Pymol 4.2 and compared with Gilbenclamide, a known agonist of PPAR-γ. Our present study reports the phytochemical analysis of the extracts of the seeds and leaves of Hunteria umbellata. 21 compounds were revealed through GC-MS analysis and screened using Autodock/Vina against PPAR-γ. Docking studies recommended that 2,2-Benzylidenebis (3-methylbenzofuran) an existing phytochemical from the seed of Hunteria umbellata had the highest fitness score of -11.3 Kcal/mol and hence could be a potent antidiabetic drug. Hunteria umbellata seed extract and its compound 2,2-Benzylidenebis (3-methylbenzofuran) have a significant antidiabetic activity against  PPAR-γ. Molecular binding interaction of an in-silico data demonstrated that 2,2-Benzylidenebis (3-methylbenzofuran) has more specificity towards the  PPAR-γ binding site and could be a potent antidiabetic compound.